（记者 王晓波） 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 每经AI快讯，海思科1月5日晚间发布公告称，公司第五届第三十三次董事会会议于2026年1月5日以通 讯表决方式召开。会议审议了《关于注销控股子公司暨关联交易的议案》等文件。 ...

格隆汇1月5日丨海思科(002653.SZ)公布，为进一步整合和优化现有资源配置，提升公司经营质量，决 定注销开曼子公司HEXGENPHARMACEUTICAL GROUP LIMITED（简称"海思锦医药"）和其下属全 资美国子公司 HEXGEN PHARMACEUTICAL HOLDING LIMITED（简称"美国海思锦"），并授权公司 经营管理层办理相关注销事宜。 ...

证券代码：002653 证券简称：海思科 公告编号：2026-002 海思科医药集团股份有限公司 关于注销控股子公司暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 （一）海思科医药集团股份有限公司（以下简称"公司"）于 2026 年 1 月 5 日召开公司第五届董事会第三十三次会议，审议通过 了《关于注销控股子公司暨关联交易的议案》，为进一步整合和优化 现有资源配置，提升公司经营质量，决定注销开曼子公司 HEXGEN PHARMACEUTICAL GROUP LIMITED（以下简称"海思锦医药"）和其下 属全资美国子公司 HEXGEN PHARMACEUTICAL HOLDING LIMITED（以下 简称"美国海思锦"），并授权公司经营管理层办理相关注销事宜。 （二）海思锦医药为公司全资子公司 HEXGEN HOLDINGS LIMITED 与关联法人 BLUE PULSE HOLDINGS PTE. LTD.共同投资企业，HEXGEN HOLDINGS LIMITED 持股 80%、BLUE PULSE HOLDING ...

证券代码：002653 证券简称：海思科 公告编号：2026-001 海思科医药集团股份有限公司 第五届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）第五届董事 会第三十三次会议（以下简称"会议"）于 2026 年 1 月 5 日以通讯 表决方式召开。会议通知于 2025 年 12 月 31 日以邮件方式发出。会 议应出席董事 5 人，以通讯表决方式出席董事 5 人。会议由公司董事 长王俊民先生召集并主持。本次会议的通知、召开以及参与表决董事 人数均符合有关法律、法规、规则及《公司章程》的有关规定。全体 董事经过审议，以投票表决方式通过了如下决议： 关联董事王俊民先生回避表决，公司独立董事对该事项进行了事 前审议。 为进一步整合和优化现有资源配置，提升公司经营质量，决定注 销关联控股子公司 HEXGEN PHARMACEUTICAL GROUP LIMITED 和其下属 全资子公司 HEXGEN PHARMACEUTICAL HOLDING LIMITED。 详见同日刊登于巨潮资讯网 ...

格隆汇12月30日丨海思科(002653.SZ)公布，子公司上海海思盛诺医药科技有限公司于近日收到国家药 品监督管理局下发的《受理通知书》，基本情况如下： HSK50042是公司自主研发的口服、强效、高选择性小分子抑制剂药物，拟用于呼吸系统疾病的治疗。 HSK55879片是公司自主研发的具有独立知识产权的口服小分子激动剂药物，拟用于代谢系统疾病的治 疗。 | 药品名称 | 剂型 | 申请事项 | 适应症 | 受理号 | | --- | --- | --- | --- | --- | | HSK50042 | 片剂 | 境内生产药品 | 呼吸系统疾病 | CXHL2501481 | | | | | | CXHL2501482 | | HSK55879 | | 注册临床试验 | 代谢系统疾病 | CXHL2501486 | | | | | | CXHL2501487 | | | | | | CXHL2501489 | ...

Group 1 - The core investment theme for the pharmaceutical industry in 2025 is the overseas expansion of innovative drugs, which is expected to yield excess returns compared to the broader pharmaceutical sector and the CSI 300 index [2][21] - The innovative drug index has shown a significant increase, outperforming the pharmaceutical biological index by 37.48 percentage points, with a year-to-date increase of 65.99% [21] - Major transactions in the ADC and dual antibody fields are anticipated to continue, while there is a need to avoid repetitive competition in areas like small nucleic acids and focus on unmet clinical needs [3][4] Group 2 - The report emphasizes the importance of overseas markets for both innovative drugs and medical devices, suggesting that companies should seek growth opportunities beyond domestic market saturation [4][5] - The Chinese pharmaceutical industry is gradually becoming a global innovation center, with significant advancements in dual antibodies and ADCs, while also making strides in emerging fields like small nucleic acids and inhalation formulations [5][6] - The report highlights that the overseas authorization revenue has become a crucial funding source for innovative drug development, with a total upfront payment of $4.551 billion in the first three quarters of 2025 [29][32] Group 3 - The medical device sector is experiencing a shift towards overseas expansion, with a focus on high-value consumables and IVD products, as Chinese companies enhance their market share [7][55] - The export growth of high-value consumables is significant, with a recorded increase of 10.75% in the first half of 2025, particularly in the North American and European markets [57][66] - The report notes that the certification and market establishment processes for high-value consumables are long-term investments, requiring compliance with stringent regulations in the EU and the US [60][61] Group 4 - The recovery of financing in the domestic innovative drug sector has been robust, with a total of 324 financing events amounting to $5.51 billion in the first three quarters of 2025, marking a 67.6% increase year-on-year [70][72] - The CXO industry is experiencing varied recovery rhythms across different segments, with some areas like CDMO seeing order growth due to overseas financing recovery [74]

Group 1 - The core viewpoint of the news is that 海思科 (Haisco) has shown a slight increase in stock price, reaching 51.14 yuan per share, with a total market capitalization of 57.273 billion yuan as of December 31 [1] - 海思科's main business involves the research, development, production, and sales of chemical pharmaceuticals, with revenue composition as follows: anesthetic products 39.81%, cooperative product-related income 23.59%, other indications 17.02%, parenteral nutrition 10.32%, antiemetics for tumors 8.15%, and other (supplementary) 0.86% [1] Group 2 - 中欧医疗健康混合A (China Europe Medical Health Mixed A) fund has increased its holdings in 海思科 by 121,200 shares, bringing its total to 21,397,500 shares, which accounts for 4.44% of the circulating shares [2] - The fund has achieved a year-to-date return of 13.6% and a one-year return of 11.58%, ranking 5,297 out of 8,085 in its category [2] Group 3 - The fund manager of 中欧医疗健康混合A is 葛兰 (Gelan) and 赵磊 (Zhao Lei), with total fund assets of 435.44 billion yuan and 329.54 billion yuan respectively [3] - 葛兰 has a tenure of 10 years and 340 days, with the best fund return of 97.86% and the worst return of -35.13% during her tenure [3] Group 4 - 中欧医疗健康混合A has 海思科 as its tenth largest holding, representing 3.47% of the fund's net value, with a floating profit of approximately 11.1267 million yuan [4]

Group 1 - Zijin Mining expects a net profit of approximately 51-52 billion yuan for 2025, representing a year-on-year increase of about 59%-62% due to growth in gold, copper, and silver production and sales prices, along with a significant increase in lithium carbonate production [1] - Tianpu Co. has seen its stock price rise by 718.39% from August 22 to December 30, leading to a suspension for stock trading review due to significant deviation from the company's fundamentals [1] - Salt Lake Co. plans to acquire 51% of Wenkang Salt Lake for 4.605 billion yuan, which will enhance its competitive edge in lithium and potassium resource development [1] Group 2 - Mingde Bio intends to acquire 100% of Wuhan Bikaier Rescue Supplies Co. in a cash transaction, which is expected to constitute a major asset restructuring [2] - Jiamei Packaging has announced that it may apply for a trading suspension if its stock price continues to rise abnormally, despite no significant changes in its fundamentals [2] Group 3 - Jinpan Technology signed a contract worth approximately 696 million yuan for an overseas data center project, which is expected to positively impact the company's long-term performance [3] Group 4 - China Pharmaceutical plans to acquire 70% of Zezheng Pharmaceutical for 525 million yuan [4] - Shengxin Lithium Energy intends to acquire 30% of Qicheng Mining for 2.08 billion yuan to increase its control over Huirong Mining [5] - China Aluminum's subsidiary plans to acquire 51% of Yun Aluminum Logistics for 264 million yuan [5]

证券日报网讯12月30日，海思科（002653）发布公告称，公司于近日收到国家药品监督管理局下发的 《药物临床试验批准通知书》，药品名称：HSK44459。 ...

Group 1 - China Medical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan to enhance its R&D capabilities in the pharmaceutical sector [1] - Hongchang Electronics has commenced production of its functional high-end copper-clad laminate electronic materials project [2] - China State Construction has secured multiple major projects totaling 32.09 billion yuan, which represents 1.5% of its audited revenue for 2024 [3] Group 2 - China Resources Double Crane has established an industrial fund with a committed investment of 83 million yuan, targeting a total fundraising goal of 500 million yuan [4] - Pinggao Electric and its subsidiaries have won state grid procurement projects worth approximately 876 million yuan, accounting for 7.06% of its 2024 revenue [5] - Dong'an Power received a government subsidy of 2.47 million yuan, with 1.47 million yuan related to assets and 1 million yuan related to income [6] Group 3 - Nantian Information has paid overdue taxes and penalties totaling 50.31 million yuan, which will impact its net profit for 2025 [7] - Erli Six has changed its investment plan to establish a wholly-owned subsidiary in Hong Kong for submarine cable business with an investment of 320 million yuan [8] - Dream Lily plans to invest 170 million yuan in an e-commerce warehouse project at its East US factory [9] Group 4 - Shen Shen Fang A's controlling shareholder has terminated the agreement to transfer 7.07% of the company's shares to Dongfang Asset, with no change in control [10] - Tianfu Culture has signed strategic cooperation framework agreements with various cultural and tourism bureaus to promote film and tourism integration [11] - Jinzi Tianzheng's chairman has resigned due to work adjustments, but will continue to fulfill his duties until a new chairman is elected [12] Group 5 - Jiangshan Oupai and its subsidiaries received government subsidies totaling 10.04 million yuan, with 7.51 million yuan related to income [13] - Ninghu Expressway plans to increase its investment in Jiangsu Danjin Expressway Co., Ltd. by 128 million yuan to support highway construction [14] - Jiangyin Bank has received approval for the qualifications of its employee director and vice president [15] Group 6 - Aoxiang Pharmaceutical has received approval for the listing application of two chemical raw materials [16] - Daye Co. has not yet commenced mass production of its robotic tendon products, with ongoing uncertainties in technology and profitability [17] - Rongsheng Environmental has proposed a cash dividend of 3.8 yuan per 10 shares, totaling approximately 97.36 million yuan [19] Group 7 - Yunyi Electric plans to invest 66 million USD in Morocco to establish a wholly-owned subsidiary and production base [20] - Derun Electronics has reached an agreement regarding the delayed payment of 100 million yuan in equity transfer funds [21] - Baihua Pharmaceutical is planning a change in control, leading to a continued suspension of its stock [22] Group 8 - CITIC Bank's executive director and president has resigned due to work adjustments [23] - Haizike's subsidiary has received acceptance for clinical trial applications for two innovative drugs [24] - Tianrun Dairy's subsidiaries received government subsidies totaling 21.53 million yuan, representing 49.32% of its net profit for 2024 [25] Group 9 - Andisou plans to issue 398 million A-shares at 7.54 yuan per share, raising a total of 3 billion yuan [26][27] - Fuda Co. has completed the transfer of its 50% stake in a joint venture, which is expected to positively impact its 2025 financial results [28] - Jianghua Micro has received environmental approval for a project to produce 37,000 tons of ultra-pure wet electronic chemicals [29] Group 10 - Nanwang Technology received a government subsidy of 10 million yuan, accounting for 0.66% of its net assets for 2024 [30] - Changgao Electric New has won state grid procurement projects totaling 161 million yuan, representing 9.14% of its 2024 revenue [31] - Huaxin Precision plans to invest up to 600 million yuan of idle funds in low-risk financial products [32] Group 11 - Fuguang Co. received a government subsidy of 1.26 million yuan for basic research projects, which is 13.27% of its net profit for 2024 [33] - Benli Technology has obtained a drug production license, which will help optimize its product structure [34] - Jintuo Co. proposed a cash dividend of 4.1 yuan per 10 shares, totaling approximately 99.48 million yuan [35] Group 12 - Kang Enbei has elected a new chairman and vice chairman during its board meeting [36] - Sanyuan Bio has completed the construction and installation of equipment for the remaining capacity of its 20,000-ton alulose project [38]